For ten years we told you where your prescribers and patients get stuck. Here's the part that fixes it.

Eight-plus indications, one portal — and oncologists can’t find the data for the patient in front of them. The agent asks who they’re treating, then routes to the right PACIFIC, AEGEAN, or ADRIATIC trial, dosing, or an MSL. Try it below.

Patients hit “not available for government-insured patients” and abandon — the exact rage-quit in your reviews. The agent catches them at the Medicare exclusion and offers the honest AZ&Me off-ramp before they leave. Try it below.

A prescriber managing hyperkalemia faces the call Lokelma was built for: hold RAASi, or add a binder? The agent settles it in-session — RAASi-continuation guidance, titration, and right-patient ID. Try it below.

A personalized read on Pulse for AstraZeneca: the decade and 18 brand programs we’ve run on your pages, the shift from measuring friction to resolving it in-session, and the NJT proof that it lifts conversion.

Adjust sessions, friction rate, agent engagement, and value per resolved event. Get AstraZeneca-specific savings-card recovery and script-lift projections in real time.

What our Voice-of-Customer research surfaced on Lokelma, the in-session reframe the agent delivers, the measurement plan, and a pilot scoped to a single success metric.

The four-layer enterprise program: standardized friction measurement, in-session intervention agents, proof of script lift, and cross-brand intelligence that compounds with every brand you add.

We mapped exactly where AstraZeneca’s prescriber and patient journeys break — indication routing, biomarker pathways, the savings-card dead-end — and the agent that recovers each one.